A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.
Clinical trial NCT03894150 · COMPLETED
Trial details
- NCT number
- NCT03894150
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-11
- Primary completion
- 2020-07-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.